Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5122131 | 0.88 | SLC16A1 (0.39) | SLC16A1LMNAADORA2B | |
| SCHEMBL5097873 | 0.81 | SLC16A1 (0.41) | SLC16A1HSD17B10HPGDMAPTLMNA | |
| SCHEMBL5096942 | 0.79 | SLC16A1 (0.38) | SLC16A1MAPTLMNAPOLBGAA | |
| SCHEMBL5093501 | 0.79 | SLC16A1 (0.37) | SLC16A1HPGDMAPTLMNAPOLB | |
| SCHEMBL5093440 | 0.78 | SLC16A1 (0.39) | SLC16A1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5107028 | 0.76 | LMNA (0.35) | SLC16A1HSD17B10HPGDMAPTLMNA | |
| SCHEMBL5120600 | 0.75 | GAA (0.36) | SLC16A1HPGDMAPTLMNAPOLB | |
| SCHEMBL5097135 | 0.73 | SLC16A1 (0.48) | SLC16A1 | |
| SCHEMBL5138945 | 0.73 | SLC16A1 (0.56) | SLC16A1HPGDLMNAALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL5099848 | 0.73 | SLC16A1 (0.47) | SLC16A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7384951-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | disclosed |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | C5, HRH4, CYP2S1 | SLC16A1 4250/4885HSD17B10 2510/4885HPGD 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.